[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gum-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gum-disease":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,69,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100621955","cheer-oral-health-in-pregnancy-study-100621955",false,"NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study","FEMALE","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[27,28,29,30,31,32,33],"Gingivitis","Dental Health","Pregnancy","Pregnancy Outcomes","Randomized Controlled Trial","Periodontal Disease","Gum Disease","NOT_YET_RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":21},"2026-09-30",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"University of California, San Francisco","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100650965","impact-of-an-arginine-containing-toothpaste-on-the-subgingival-microbiota-in-patients-in-supportive-periodontal-care-100650965","NCT07755800","Impact of an Arginine-containing Toothpaste on the Subgingival Microbiota in Patients in Supportive Periodontal Care","Inclusion Criteria:\n\n* Understands and is willing to sign an Informed Consent, approved by the local Ethics Committee.\n* Female or male, ages 18-95 years old (inclusive)\n* Systemically healthy.\n* Presence of at least three evaluable teeth in each quadrant.\n* Moderate gingival inflammation, with at least a 10% of bleeding on probing (BOP) will be required together with moderate level of plaque.\n* No Grade 3 Tooth Mobility\n* Treated stage II or III periodontitis patients, whose active treatment has finalized more than 6 months before. Stage II - Interdental clinical attachment level (CAL) at the site of greatest loss equal to 3 to 4 millimeters with maximum probing depth of less than or equal to 5 millimeters. Stage III - Interdental CAL at the site of greatest loss greater than equal to 5 millimeters, probing depth (PD) greater than or equal to 6 millimeters, and radiographic vertical bone loss\n* Enrolled in a periodontal maintenance treatment program\n* No orthodontic banding (no permanent retainers, no orthodontic appliances (i.e., no removable plastic\u002Fmetal retainer) or removable prosthesis (no removable partial and\u002For full denture).\n* Subjects willing to participate and comply with the requirements of the study.\n* Subjects that brush their teeth regularly (once or twice daily).\n* Able to travel to and attend 4 research study visits over the span of the next 6 months.\n* Able to independently provide consent for oneself.\n* Fluent in reading, comprehending, and speaking English without assistance from a translator.\n* If a patient is using prevident, they must be willing to stop using it.\n\nExclusion Criteria:\n\n* Untreated or uncontrolled periodontitis or advanced (advanced periodontal disease (purulent exudate, tooth mobility, and\u002For extensive alveolar bone loss)\n* Antibiotics intake within the previous month.\n* Pregnant women and\u002For breastfeeding women\n* Any adverse medical history (controlled and uncontrolled diabetes, osteoporosis, immunosuppression…) or long-term medication (chemotherapy and immunosuppression treatment; pharmacological treatment associated with gingival overgrowth such as the use of phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, amlodipine, verapamil, cyclosporine) influencing gingival conditions.\n* Conditions which require antibiotic prophylaxis (infectious endocarditis, cardiac valve prosthesis…).\n* Not willing to comply with the study protocol recommendation and visit schedule.\n* Current smokers or those using tobacco or vaping products.\n* Five (5) or more decayed, untreated dental sites (cavities) and\u002For any dental condition requiring urgent dental care\n* Currently participating in another clinical research study now and\u002For within the past month.\n* Has a history of allergies to oral care or personal care consumer products or their ingredients\n* Has an existing medical condition that prohibits eating or drinking for periods up to 4 hours.\n* Any ongoing medical condition that makes a subject unsuitable for enrollment-or any new diagnosis that arises during the study that makes the subject unsuitable to continue-may lead to exclusion, as determined by the Principal Investigator on a case by case basis. Conditions that may result in exclusion include, but are not limited to:\n\n  1. Recent myocardial infarction\n  2. Recent cerebrovascular accident\n  3. Recent placement of a cardiac valvular prosthesis\n  4. Severe liver dysfunction\n  5. Known or suspected current malignancy\n  6. New antibiotic use\n  7. Note: The Principal Investigator will review all available information about the subject and make decisions regarding both enrollment and\u002For continued participation.","ALL","95 Years",{"count":56,"type":21},108,[24],"This study aims to see how a toothpaste with arginine affects bacteria below the gum line compared to a regular fluoride toothpaste. It focuses on people with gum disease who are already getting ongoing dental care.\n\nThe main questions it aims to answer are:\n\n* How does an arginine toothpaste affect the bacteria below the gumline?\n* How does a fluoride toothpaste affect the bacteria below the gumline?\n\nParticipants will:\n\n* Use fluoride toothpaste or arginine toothpaste twice daily for 6 months\n* After receiving the toothpaste at the baseline visit, subjects will visit the clinic at 3 months and 6 months for additional data collection.",[33],"2026-08-04",{"date":62,"type":38},"2026-08-10",{"date":64,"type":21},"2026-08",{"date":66,"type":21},"2028-07",{"name":68,"class":45},"Sukirth M Ganesan, BDS, PhD",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":53,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100566526","an-evaluation-of-the-effect-of-the-erchonia-fx-405-laser-as-an-adjunctive-treatment-of-periodontitis-100566526","NCT06656325","An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis","An Evaluation of the Effect of the Erchonia Corporation FX-405 Laser as an Adjunctive Treatment of Periodontitis","Inclusion Criteria:\n\n* Subject has voluntarily signed a written informed consent form.\n* Male or female 22 to 75 years of age, inclusive.\n* Subject has no evidence of Localized Aggressive Periodontitis.\n* Tooth loss due to periodontitis of ≤ 4 teeth.\n* Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months\n* Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.\n* Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.\n* Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.\n* Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study\n\nExclusion Criteria:\n\n* Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.\n* History of oral cancer or HIV in the last 6 months\n* Pregnant or intending to become pregnant in the next 8 months.\n* Sensitivity to, or contraindication for, light therapy.\n* Currently enrolled in a clinical study of an investigational drug or device.","22 Years","75 Years",{"count":79,"type":21},70,[24],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.",[83,84,33],"Periodontal Diseases","Periodontitis","RECRUITING","2026-05-14",{"date":88,"type":38},"2026-05-18",{"date":90,"type":38},"2025-01-01",{"date":92,"type":21},"2027-08-01",{"name":94,"class":95},"Erchonia Corporation","INDUSTRY",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":46},"100591459","improving-oral-and-systemic-health-in-individuals-with-prediabetes-through-personalized-oral-hygiene-advice-provided-by-dentists-or-by-ai-100591459","NCT06980701","Improving Oral and Systemic Health in Individuals With Prediabetes Through Personalized Oral Hygiene Advice Provided by Dentists or by AI","Improving Oral and Systemic Health in Individuals With Prediabetes Through Personalized Oral Hygiene Advice Provided by Dentists or by Artificial Intelligence: A Randomized Clinical Trial","Inclusion Criteria:\n\n* \\- Subjects who are \\>18 years of age and able to give informed consent.\n* \\- Subjects who are mentally and cognitively healthy.\n* \\- Subjects who have at least 6 anterior maxillary or mandibular natural teeth including incisors and canine.\n* \\- Subjects who are with prediabetic state with impaired HbA1c 5.7% to 6.4%, impaired fasting plasma glucose level 5.6mmol\u002FL to 6.9 mmol\u002FL and\u002For impaired plasma glucose level after 2h OGTT 7.8 mmol\u002FL to 11.0 mmol\u002FL.\n* \\- Subjects who can speak, read, or understand Cantonese to complete the satisfaction questionnaire.\n* \\- Subjects who can practice oral hygiene procedure (regular tooth brushing and interdental cleansing\u002Fflossing\u002Fbrushing) daily on their own independently.\n\nExclusion Criteria:\n\n* \\- Subjects who have less than 6 anterior maxillary or mandibular natural teeth with or without dental prostheses in those area.\n* \\- Subjects who are with a current diagnosis or clinical history of T2DM.\n* \\- Subjects who have mental illness, or similar problems that unable to complete the satisfaction questionnaire.\n* \\- Subjects who cannot perform oral hygiene procedure (regular tooth brushing and interdental cleansing\u002Fflossing\u002Fbrushing) by any condition of oral cavity such as tumor or maxillomandibular fixation.",{"count":105,"type":21},148,[24],"Prediabetes is an intermediate stage before the development of diabetes, characterized by elevated blood glucose levels but lower than the diagnostic criteria of diabetes and is associated with multiple long-term complications. This systemic disease is mutually linked to inflammatory gum diseases through circulating inflammatory mediators. Controlling inflammatory gum diseases improves blood glucose levels and reduces long-term complications. While maintaining good oral hygiene through home care is essential for managing inflammatory gum diseases, close supervision of patients' home care is labor-intensive and expensive. Artificial Intelligence (AI) has been used to provide personalized advice on the adequacy of patients' home care (oral hygiene). The investigators hypothesize that the use of AI can improve home care, thereby enhancing both gum health and systemic health, similar to human dental professionals.",[33,109],"Prediabetes",[111,112,113,114],"gum disease","prediabetes","oral health","oral hygiene","2025-11-25",{"date":117,"type":38},"2025-12-03",{"date":119,"type":38},"2025-04-12",{"date":121,"type":21},"2026-04-18",{"name":123,"class":45},"The University of Hong Kong"]